// App-Quantinova.ai

e17569 : Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

Researchers

Presenter

  • Shruti U. Gandhy

Principal Investigators

  • Fatima Karzai

  • Jennifer L. Marte

  • Marijo Bilusic

  • Sheri McMahon

  • Julius Strauss

  • Anna Couvillon

  • Monique Williams

  • Amy Hankin

  • Seth M. Steinberg

  • Audrey Gill

  • Alisa Tubbs

  • Joseph Schonhoft

  • William Douglas Figg

  • Philip M. Arlen

  • William L. Dahut

  • James L. Gulley

  • Ravi Amrit Madan

Medical Centers

  • National Cancer Institute, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • CCR, NIH, Bethesda, MD

  • Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CVac

  • Enzalutamide

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • NA

Study Id's

  • NCT01867333

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved